Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
American Society of Hematology (ASH)
The
American Society of Hematology
(
ASH
) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal
Blood
, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal,
Blood Advances
.
Management of Adverse Events in the HELIOS Trial in Patients with Previously Treated CLL/SLL
ASH 2015 – Castleman's Disease, Lymphoma & CLL
Read More ›
Existing Oral and IV Therapies
ASH 2015 – Multiple Myeloma
Ali McBride discusses medicines that have been on the market for the last few years.
Read More ›
Getting New Therapies to Patients
ASH 2015 – Multiple Myeloma
Ali McBride speaks to the challenges of medication adherence, especially in the various settings.
Read More ›
Abexinostat in Patients with NHL and CLL: Results of an Ongoing Phase 2 Study
ASH 2015 – Castleman's Disease, Lymphoma & CLL
Read More ›
The Pharmacist and Oral Oncolytics
ASH 2015 – Multiple Myeloma
R. Donald Harvey discusseses his role in managing patients on this medication class.
Read More ›
Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Relapsed/Refractory NHL
ASH 2015 – Castleman's Disease, Lymphoma & CLL
Read More ›
Venetoclax (ABT-199/GDC-0199) plus Bendamustine/Rituximab in Relapsed/Refractory NHL: Results of a Dose-Escalation Study
ASH 2015 – Castleman's Disease, Lymphoma & CLL
Read More ›
Patient Access to Oral Oncolytics
ASH 2015 – Multiple Myeloma
Ali McBride talks about patient issues with medication adherence and what payers are doing to ensure compliance.
Read More ›
R-CHOP ± Bortezomib in Patients with Untreated Non-GCB DLBCL: Results from the Phase 2 PYRAMID Trial
ASH 2015 – Castleman's Disease, Lymphoma & CLL
Read More ›
Ibrutinib versus Chlorambucil in Patients >65 Years with Treatment-Naïve CLL/SLL: Results from the Phase 3 RESONATE-2 Study
ASH 2015 – Castleman's Disease, Lymphoma & CLL
Read More ›
Page 39 of 44
36
37
38
39
40
41
42
Conference Coverage Proudly Presented by
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us